Compare Sana Biotechnology Inc (SANA) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Suncor Energy Inc. — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Suncor Energy Inc. trades at $63.7 (market cap $72.86B). The key difference: Suncor Energy Inc. is far larger — about 83.4× Sana Biotechnology Inc's market cap, and Suncor Energy Inc. pays a 2.71% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SU | |
|---|---|---|
Market Cap | $873.84M | $72.86B |
Sector | Health | Energy |
52-Week High | $5.92 | $69.73 |
52-Week Low | $2.68 | $38.17 |
Enterprise Value | $848.03M | $80.99B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Suncor Energy (SU) trades at $63.70, up 2.03% today, with a bullish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but beat in the prior two quarters. Valuation ratios appear reasonable with a P/E of 16.8 and EV/EBITDA of 7.08. Strong profitability is evident with a net income margin of 11.62% and ROE of 13.97%. A dividend of $0.60 per share is scheduled for payment on June 25, 2026.
The outlook for SU is supported by record production and integrated operations, but faces risks from oil price volatility and operational incidents. Analyst consensus is strongly bullish with 74% buy ratings. The stock's performance hinges on upcoming Q2 2026 results and broader energy market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
